Department of Genetic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Central Manchester Foundation Trust, St Mary's Hospital, 6th Floor, Oxford Road, Manchester M13 9WL, UK.
Br J Cancer. 2011 Jun 28;105(1):22-7. doi: 10.1038/bjc.2011.202. Epub 2011 Jun 7.
Women at high ovarian cancer risk, especially those with mutations in BRCA1/BRCA2, are encouraged to undergo bilateral risk-reducing salpingo-oophorectomy (BRRSPO) prior to the natural menopause. The decision to use HRT to cover the period of oestrogen deprivation up to 50 years of age is difficult because of balancing the considerations of breast cancer risk, bone and cardiovascular health.
We reviewed by questionnaire 289 women after BRRSPO aged ≤48 years because of high ovarian cancer risk; 212 (73%) of women responded.
Previous HRT users (n=67) had significantly worse endocrine symptom scores than 67 current users (P=0.006). A total of 123 (58%) of women had ≥24 months of oestrogen deprivation <50 years with 78 (37%) never taking HRT. Bone density (DXA) evaluations were available on 119 (56%) women: bone loss with a T score of ≤-1.0 was present in 5 out of 31 (16%) women with no period of oestrogen deprivation <50 years compared with 37 out of 78 (47%) of those with ≥24 months of oestrogen deprivation (P=0.03).
Women undergoing BRRSPO <50 years should be counselled concerning the risks/benefits of HRT, taking into consideration the benefits on symptoms, bone health and cardiovascular health, and that the risks of breast cancer from oestrogen-only HRT appear to be relatively small.
高卵巢癌风险的女性,尤其是携带 BRCA1/BRCA2 突变的女性,被鼓励在自然绝经前进行双侧降低风险的输卵管卵巢切除术(BRRSPO)。由于需要平衡乳腺癌风险、骨骼和心血管健康等因素,决定是否使用激素替代疗法(HRT)来覆盖 50 岁之前的雌激素缺乏期是非常困难的。
我们通过问卷调查,对 289 名因高卵巢癌风险而在 ≤48 岁时接受 BRRSPO 的女性进行了回顾性研究;212 名(73%)女性做出了回应。
既往 HRT 使用者(n=67)的内分泌症状评分显著高于当前使用者(n=67)(P=0.006)。共有 123 名(58%)女性经历了 <50 岁的雌激素缺乏期 ≥24 个月,其中 78 名(37%)从未使用过 HRT。119 名(56%)女性的骨密度(DXA)评估结果可用:在没有 <50 岁的雌激素缺乏期的 31 名女性中,有 5 名(16%)的骨密度损失 T 评分≤-1.0,而在有 ≥24 个月雌激素缺乏期的 78 名女性中,有 37 名(47%)的骨密度损失 T 评分≤-1.0(P=0.03)。
接受 BRRSPO 的女性年龄 <50 岁时,应考虑 HRT 的风险/获益,考虑到其对症状、骨骼健康和心血管健康的益处,以及单纯雌激素 HRT 的乳腺癌风险似乎相对较小。